Among available immunotherapies, the use of “CAR-T” cells is proving extremely effective against certain blood cancers, but only in half of patients. A main reason for this is the premature dysfunction of these immune cells, which have been artificially modified in vitro. A team from the Universities of Geneva (UNIGE), Lausanne (UNIL), the Geneva University… Read More »